Title: Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
Version: 2 Date: 04 May 2023
Reviewer's report:
The article reports that triptolide ameliorates IBS in a rat model and explores the initial target of
action as ODC1. The article is somewhat innovative. However, there are the following problems:
1.  In the Animal Model and Treatment section the authors wrote: All the rats were randomly
divided into 3 groups (n = 6 each): the normal group administered via gavage of the same All the
rats were randomly divided into 3 groups (n = 6 each): the normal group administered via gavage
of the same volume of olive oil, the IBS group, and the IBS treated via gavage of triptolide
(100µg/kg/day).
What is the rationale for describing the dose of triptolide as 100µg/kg/day? Is there any literature
that supports its efficacy and safety? Please add the appropriate references if available.
2. The introduction section does not describe how Ornithine Decarboxylase-1 is linked to IBS.
3.  In the results section, the authors should describe whether the modeling method used
successfully induced IBS in rats.
Title: Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
Version: 2 Date: 04 May 2023
Reviewer's report:
The article reports that triptolide ameliorates IBS in a rat model and explores the initial target of
action as ODC1. The article is somewhat innovative. However, there are the following problems:
1.  In the Animal Model and Treatment section the authors wrote: All the rats were randomly
divided into 3 groups (n = 6 each): the normal group administered via gavage of the same All the
rats were randomly divided into 3 groups (n = 6 each): the normal group administered via gavage
of the same volume of olive oil, the IBS group, and the IBS treated via gavage of triptolide
(100µg/kg/day).
What is the rationale for describing the dose of triptolide as 100µg/kg/day? Is there any literature
that supports its efficacy and safety? Please add the appropriate references if available.
2. The introduction section does not describe how Ornithine Decarboxylase-1 is linked to IBS.
3.  In the results section, the authors should describe whether the modeling method used
successfully induced IBS in rats.
Please review this paper.
user
Title: Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
Version: 2 Date: 04 May 2023
Reviewer's report:
The article reports that triptolide ameliorates IBS in a rat model and explores the initial target of
action as ODC1. The article is somewhat innovative. However, there are the following problems:
1.  In the Animal Model and Treatment section the authors wrote: All the rats were randomly
divided into 3 groups (n = 6 each): the normal group administered via gavage of the same All the
rats were randomly divided into 3 groups (n = 6 each): the normal group administered via gavage
of the same volume of olive oil, the IBS group, and the IBS treated via gavage of triptolide
(100µg/kg/day).
What is the rationale for describing the dose of triptolide as 100µg/kg/day? Is there any literature
that supports its efficacy and safety? Please add the appropriate references if available.
2. The introduction section does not describe how Ornithine Decarboxylase-1 is linked to IBS.
3.  In the results section, the authors should describe whether the modeling method used
successfully induced IBS in rats.
assistant